首页> 外文期刊>Forbes >Brain Repair
【24h】

Brain Repair

机译:脑部修复

获取原文
获取原文并翻译 | 示例
           

摘要

The drug industry has a dismal track record against stroke, the nation's third-biggest killer. At least 20 antistroke compounds have entered large human trials in recent years after promising lab results, but only one, Genentech's clot-buster Activase, has made it to the market. Even so, its effects are limited, and it is rarely used. Almost all of the rest have proven ineffective or even dangerous. Faced with such long odds, some drug firms have given up. A handful of determined biotech companies plug on, determined to learn from all the failures and find a compound that works. The need couldn't be more urgent: 700,000 Americans suffer strokes each year, leading to 160,000 deaths and $51 billion in disability-related costs. "A neuroprotectant drug that actually works will have a profound impact on society," says neuroscien-tist Corey Goodman, chief executive of Renovis, which, in conjunction with AstraZeneca, is testing a drug it hopes will fill the bill. "The first drug that has any efficacy, even very small, will get used a lot," says Wade Smith, a neurologist and neurovascular stroke specialist at the University of California, San Francisco.
机译:制药业在打击中风方面有着惨淡的记录,中风是美国第三大杀手。在获得可喜的实验室结果后,近年来至少有20种抗中风化合物已进入大规模的人体试验,但是只有一种,Genentech的血栓破坏性活化酶已经投放市场。即使这样,它的作用还是有限的,并且很少使用。其余的几乎全部被证明是无效的,甚至是危险的。面对如此长的困难,一些制药公司已经放弃了。少数坚定的生物技术公司加入其中,决心从所有失败中汲取教训,并找到可行的化合物。迫在眉睫的需求迫在眉睫:每年有700,000美国人中风,导致160,000例死亡和510亿美元的残疾相关成本。 Renovis首席执行官神经科医师Corey Goodman说:“一种有效的神经保护药物将对社会产生深远影响。”该公司与阿斯利康(AstraZeneca)一起正在测试一种药物,希望该药物能够解决该问题。加州大学旧金山分校的神经病专家和神经血管性中风专家韦德·史密斯说:“第一种几乎没有任何功效的药物,将被大量使用。”

著录项

  • 来源
    《Forbes》 |2004年第6期|p.110-111|共2页
  • 作者

    ROBERT LANGRETH;

  • 作者单位
  • 收录信息 美国《科学引文索引》(SCI);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 世界经济问题;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号